Antitumor virotherapy by attenuated measles virus (MV

Biology

Volumn 2, Issue 2, 2013, Pages 587-602

  Guillerme, Jean Baptiste ^a,b,c   Gregoire, Marc ^a,b,c   Tangy, Frédéric ^d   Fonteneau, Jean François ^a,b,c  

^a Groupe de Recherche Cytokines et Récepteurs en Immuno Cancérologie   (France)

^b UMR 7359   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

Antitumor virotherapy; Clinical trial; Dendritic cells; Measles virus vaccine; Tumor antigen; Vaccine

Indexed keywords

EID: 84886943477     PISSN: None     EISSN: 20797737     Source Type: Journal    
DOI: 10.3390/biology2020587     Document Type: Review

References (95)

1. Boisgerault, N.; Tangy, F.; Gregoire, M. New perspectives in cancer virotherapy: Bringing the immune system into play. Immunotherapy 2010, 2, 185-199.
2. Russell, S.J.; Peng, K.W.; Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30, 658-670.
3. Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22, 240-273, Table of Contents.
4. Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
5. Bluming, A.Z.; Ziegler, J.L. Regression of burkitt's lymphoma in association with measles infection. Lancet 1971, 2, 105-106.
6. Pasquinucci, G. Possible effect of measles on leukaemia. Lancet 1971, 1, 136.
7. Gauvrit, A.; Brandler, S.; Sapede-Peroz, C.; Boisgerault, N.; Tangy, F.; Gregoire, M. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific cd8 response. Cancer Res. 2008, 68, 4882-4892.
8. Guillerme, J.B.; Boisgerault, N.; Roulois, D.; Menager, J.; Combredet, C.; Tangy, F.; Fonteneau, J.-F.; Gregoire, M. Measles virus vaccine-infected tumor cells induce plasmacytoid dendritic cell maturation and tumor antigen cross-presentation. Clin. Cancer Res. 2013, 19, 1147-1158
9. Moss, W.J.; Griffin, D.E. Global measles elimination. Nat. Rev. Microbiol. 2006, 4, 900-908.
10. Nomenclature for describing the genetic characteristics of wild-type measles viruses (update). Wkly. Epidemiol. Rec. 2001, 76, 249-251.
11. Enders, J.F.; Peebles, T.C. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc. Soc. Exp. Biol. Med. 1954, 86, 277-286.
12. Bankamp, B.; Takeda, M.; Zhang, Y.; Xu, W.; Rota, P.A. Genetic characterization of measles vaccine strains. J. Infect. Dis. 2011, 204, S533-S548.
13. Schwarz, A.J. Preliminary tests of a highly attenuated measles vaccine. Am. J. Dis. Child. 1962, 103, 386-389.
14. Griffin, D.E.; Pan, C.H.; Moss, W.J. Measles vaccines. Front. Biosci. 2008, 13, 1352-1370.
15. World Health Organisation: Immunization, Vaccines and Biologicals: Measles. Available online: http://www.who.int/immunization/topics/measles/en/index.html/ (accessed on 24 April 2012).
16. Griffin, D. Measles virus. In Field's Virology; Knipe, D., Howley, P., Eds.; Lippincott-Raven Publishers: Philadelphia, PA, USA, 2001; Volume 2, pp. 1401-1441.
17. Lievano, F.; Galea, S.A.; Thornton, M.; Wiedmann, R.T.; Manoff, S.B.; Tran, T.N.; Amin, M.A.; Seminack, M.M.; Vagie, K.A.; Dana, A.; et al. Measles, mumps, and rubella virus vaccine (m-mrii): A review of 32 years of clinical and postmarketing experience. Vaccine 2012, 30, 6918-6926.
18. Parker Fiebelkorn, A.; Redd, S.B.; Gallagher, K.; Rota, P.A.; Rota, J.; Bellini, W.; Seward, J. Measles in the united states during the postelimination era. J. Infect. Dis. 2010, 202, 1520-1528.
19. Progress towards measles elimination in who's european region, 2005-2008. Wkly. Epidemiol. Rec. 2009, 84, 57-64.
20. Wolfson, L.J.; Strebel, P.M.; Gacic-Dobo, M.; Hoekstra, E.J.; McFarland, J.W.; Hersh, B.S. Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 2007, 369, 191-200.
21. Hilleman, M.R. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2001, 20, 651-665.
22. Hsu, E.C.; Iorio, C.; Sarangi, F.; Khine, A.A.; Richardson, C.D. Cdw150(slam) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology 2001, 279, 9-21.
23. Tatsuo, H.; Ono, N.; Tanaka, K.; Yanagi, Y. Slam (cdw150) is a cellular receptor for measles virus. Nature 2000, 406, 893-897.
24. Anderson, B.D.; Nakamura, T.; Russell, S.J.; Peng, K.W. High cd46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004, 64, 4919-4926.
25. Dorig, R.E.; Marcil, A.; Chopra, A.; Richardson, C.D. The human cd46 molecule is a receptor for measles virus (edmonston strain). Cell 1993, 75, 295-305.
26. Naniche, D.; Varior-Krishnan, G.; Cervoni, F.; Wild, T.F.; Rossi, B.; Rabourdin-Combe, C.; Gerlier, D. Human membrane cofactor protein (cd46) acts as a cellular receptor for measles virus. J. Virol. 1993, 67, 6025-6032.
27. Liszewski, M.K.; Atkinson, J.P. Membrane cofactor protein. Curr. Top. Microbiol. Immunol. 1992, 178, 45-60.
28. Fishelson, Z.; Donin, N.; Zell, S.; Schultz, S.; Kirschfink, M. Obstacles to cancer immunotherapy: Expression of membrane complement regulatory proteins (mcrps) in tumors. Mol. Immunol. 2003, 40, 109-123.
29. Ravindranath, N.M.; Shuler, C. Expression of complement restriction factors (cd46, cd55 & cd59) in head and neck squamous cell carcinomas. J. Oral Pathol. Med. 2006, 35, 560-567.
30. Peng, K.W.; TenEyck, C.J.; Galanis, E.; Kalli, K.R.; Hartmann, L.C.; Russell, S.J. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res. 2002, 62, 4656-4662.
31. Noyce, R.S.; Bondre, D.G.; Ha, M.N.; Lin, L.T.; Sisson, G.; Tsao, M.S.; Richardson, C.D. Tumor cell marker pvrl4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011, 7, e1002240.
32. Muhlebach, M.D.; Mateo, M.; Sinn, P.L.; Prufer, S.; Uhlig, K.M.; Leonard, V.H.; Navaratnarajah, C.K.; Frenzke, M.; Wong, X.X.; Sawatsky, B.; et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011, 480, 530-533.
33. Racaniello, V., Virology. An exit strategy for measles virus. Science 2011, 334, 1650-1651.
34. Mendelsohn, C.L.; Wimmer, E.; Racaniello, V.R. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 1989, 56, 855-865.
35. Lopez, M.; Cocchi, F.; Menotti, L.; Avitabile, E.; Dubreuil, P.; Campadelli-Fiume, G. Nectin2alpha (prr2alpha or hveb) and nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the leu25pro substitution in glycoprotein d. J. Virol. 2000, 74, 1267-1274.
36. Derycke, M.S.; Pambuccian, S.E.; Gilks, C.B.; Kalloger, S.E.; Ghidouche, A.; Lopez, M.; Bliss, R.L.; Geller, M.A.; Argenta, P.A.; Harrington, K.M.; et al. Nectin 4 overexpression in ovarian cancer tissues and serum: Potential role as a serum biomarker. Am. J. Clin. Pathol. 2010, 134, 835-845.
37. Takano, A.; Ishikawa, N.; Nishino, R.; Masuda, K.; Yasui, W.; Inai, K.; Nishimura, H.; Ito, H.; Nakayama, H.; Miyagi, Y.; et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res. 2009, 69, 6694-6703.
38. Fabre-Lafay, S.; Garrido-Urbani, S.; Reymond, N.; Goncalves, A.; Dubreuil, P.; Lopez, M. Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alphaconverting enzyme (tace)/adam-17. J. Biol. Chem. 2005, 280, 19543-19550.
39. Sugiyama, T.; Yoneda, M.; Kuraishi, T.; Hattori, S.; Inoue, Y.; Sato, H.; Kai, C. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment. Gene Ther. 2012, 20, 338-347.
40. Boisgerault, N.; Fonteneau, J.F.; Gregoire, M. INSERM UMR892, Nantes, France. Unpublished work, 2011.
41. Parrula, C.; Fernandez, S.A.; Zimmerman, B.; Lairmore, M.; Niewiesk, S. Measles virotherapy in a mouse model of adult t-cell leukaemia/lymphoma. J. Gen. Virol. 2011, 92, 1458-1466.
42. Grote, D.; Russell, S.J.; Cornu, T.I.; Cattaneo, R.; Vile, R.; Poland, G.A.; Fielding, A.K. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001, 97, 3746-3754.
43. Peng, K.W.; Ahmann, G.J.; Pham, L.; Greipp, P.R.; Cattaneo, R.; Russell, S.J. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001, 98, 2002-2007.
44. Penheiter, A.R.; Wegman, T.R.; Classic, K.L.; Dingli, D.; Bender, C.E.; Russell, S.J.; Carlson, S.K. Sodium iodide symporter (nis)-mediated radiovirotherapy for pancreatic cancer. AJR Am. J. Roentgenol. 2010, 195, 341-349.
45. Allen, C.; Opyrchal, M.; Aderca, I.; Schroeder, M.A.; Sarkaria, J.N.; Domingo, E.; Federspiel, M.J.; Galanis, E. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells. Gene Ther. 2012, 122, 745-754.
46. Phuong, L.K.; Allen, C.; Peng, K.W.; Giannini, C.; Greiner, S.; TenEyck, C.J.; Mishra, P.K.; Macura, S.I.; Russell, S.J.; Galanis, E.C. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003, 63, 2462-2469.
47. Iankov, I.D.; Msaouel, P.; Allen, C.; Federspiel, M.J.; Bulur, P.A.; Dietz, A.B.; Gastineau, D.; Ikeda, Y.; Ingle, J.N.; Russell, S.J.; et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res. Treat. 2010, 122, 745-754.
48. McDonald, C.J.; Erlichman, C.; Ingle, J.N.; Rosales, G.A.; Allen, C.; Greiner, S.M.; Harvey, M.E.; Zollman, P.J.; Russell, S.J.; Galanis, E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res. Treat. 2006, 99, 177-184.
49. Donnelly, O.G.; Errington-Mais, F.; Steele, L.; Hadac, E.; Jennings, V.; Scott, K.; Peach, H.; Phillips, R.M.; Bond, J.; Pandha, H.; et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 2011, 20, 7-15.
50. Meng, X.; Nakamura, T.; Okazaki, T.; Inoue, H.; Takahashi, A.; Miyamoto, S.; Sakaguchi, G.; Eto, M.; Naito, S.; Takeda, M.; et al. Enhanced antitumor effects of an engineered measles virus edmonston strain expressing the wild-type n, p, l genes on human renal cell carcinoma. Mol. Ther. 2010, 18, 544-551.
51. Li, H.; Peng, K.W.; Dingli, D.; Kratzke, R.A.; Russell, S.J. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 2010, 17, 550-558.
52. Hutzen, B.; Pierson, C.R.; Russell, S.J.; Galanis, E.; Raffel, C.; Studebaker, A.W. Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. BMC Cancer 2012, 12, 508.
53. Studebaker, A.W.; Kreofsky, C.R.; Pierson, C.R.; Russell, S.J.; Galanis, E.; Raffel, C. Treatment of medulloblastoma with a modified measles virus. Neuro. Oncol. 2010, 12, 1034-1042.
54. Boisgerault, N.; Guillerme, J.B.; Pouliquen, D.; Achard, C.; Mesel-Lemoine, M.; Combredet, C.; Fonteneau, J.F.; Tangy, F.; Gregoire, M. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. BioMed Res. Int. 2013, 2013, 387362.
55. Zhang, S.C.; Wang, W.L.; Cai, W.S.; Jiang, K.L.; Yuan, Z.W. Engineered measles virus edmonston strain used as a novel oncolytic viral system against human hepatoblastoma. BMC Cancer 2012, 12, 427.
56. Tangy, F.; Naim, H.Y. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. Viral Immunol. 2005, 18, 317-326.
57. Greiner, A.; Neumann, M.; Stingl, S.; Wassink, S.; Marx, A.; Riechert, F.; Muller-Hermelink, H.K. Characterization of wue-1, a novel monoclonal antibody that stimulates the growth of plasmacytoma cell lines. Virchows. Arch. 2000, 437, 372-379.
58. Hummel, H.D.; Kuntz, G.; Russell, S.J.; Nakamura, T.; Greiner, A.; Einsele, H.; Topp, M.S. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells. J. Gen. Virol. 2009, 90, 693-701.
59. Myers, R.; Greiner, S.; Harvey, M.; Soeffker, D.; Frenzke, M.; Abraham, K.; Shaw, A.; Rozenblatt, S.; Federspiel, M.J.; Russell, S.J.; et al. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther. 2005, 12, 593-599.
60. Galanis, E.; Hartmann, L.C.; Cliby, W.A.; Long, H.J.; Peethambaram, P.P.; Barrette, B.A.; Kaur, J.S.; Haluska, P.J., Jr.; Aderca, I.; Zollman, P.J.; et al. Phase i trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010, 70, 875-882.
61. Dingli, D.; Peng, K.W.; Harvey, M.E.; Greipp, P.R.; O'Connor, M.K.; Cattaneo, R.; Morris, J.C.; Russell, S.J. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103, 1641-1646.
62. Brem, H.; Gresser, I.; Grosfeld, J.; Folkman, J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J. Pediatr. Surg. 1993, 28, 1253-1257.
63. Le Bon, A.; Tough, D.F. Links between innate and adaptive immunity via type i interferon. Curr. Opin. Immunol. 2002, 14, 432-436.
64. Berchtold, S.; Lampe, J.; Weiland, T.; Smirnow, I.; Schleicher, S.; Handgretinger, R.; Kopp, H.G.; Reiser, J.; Stubenrauch, F.; Mayer, N.; et al. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J. Virol. 2013, 87, 3484-3501.
65. Prestwich, R.J.; Ilett, E.J.; Errington, F.; Diaz, R.M.; Steele, L.P.; Kottke, T.; Thompson, J.; Galivo, F.; Harrington, K.J.; Pandha, H.S.; et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin. Cancer Res. 2009, 15, 4374-4381.
66. Errington, F.; Steele, L.; Prestwich, R.; Harrington, K.J.; Pandha, H.S.; Vidal, L.; de Bono, J.; Selby, P.; Coffey, M.; Vile, R.; et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J. Immunol. 2008, 180, 6018-6026.
67. Kepp, O.; Tesniere, A.; Zitvogel, L.; Kroemer, G. The immunogenicity of tumor cell death. Curr. Opin. Oncol. 2009, 21, 71-76.
68. Kumar, H.; Kawai, T.; Akira, S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011, 30, 16-34.
69. Steinman, R.M. Decisions about dendritic cells: Past, present, and future. Annu. Rev. Immunol. 2012, 30, 1-22.
70. Steinman, R.M.; Lustig, D.S.; Cohn, Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. J. Exp. Med. 1974, 139, 1431-1445.
71. Joffre, O.P.; Segura, E.; Savina, A.; Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 2012, 12, 557-569.
72. Fujii, S.; Liu, K.; Smith, C.; Bonito, A.J.; Steinman, R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires cd40 ligation in addition to antigen presentation and cd80/86 costimulation. J. Exp. Med. 2004, 199, 1607-1618.
73. Krysko, D.V.; Garg, A.D.; Kaczmarek, A.; Krysko, O.; Agostinis, P.; Vandenabeele, P. Immunogenic cell death and damps in cancer therapy. Nat. Rev. Cancer 2012, 12, 860-875.
74. Bachem, A.; Guttler, S.; Hartung, E.; Ebstein, F.; Schaefer, M.; Tannert, A.; Salama, A.; Movassaghi, K.; Opitz, C.; Mages, H.W.; et al. Superior antigen cross-presentation and xcr1 expression define human cd11c+cd141+ cells as homologues of mouse cd8+ dendritic cells. J. Exp. Med. 2010, 207, 1273-1281.
75. Crozat, K.; Guiton, R.; Contreras, V.; Feuillet, V.; Dutertre, C.A.; Ventre, E.; Vu Manh, T.P.; Baranek, T.; Storset, A.K.; Marvel, J.; et al. The xc chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse cd8alpha+ dendritic cells. J. Exp. Med. 2010, 207, 1283-1292.
76. Jongbloed, S.L.; Kassianos, A.J.; McDonald, K.J.; Clark, G.J.; Ju, X.; Angel, C.E.; Chen, C.J.; Dunbar, P.R.; Wadley, R.B.; Jeet, V.; et al. Human cd141+ (bdca-3)+ dendritic cells (dcs) represent a unique myeloid dc subset that cross-presents necrotic cell antigens. J. Exp. Med. 2010, 207, 1247-1260.
77. Poulin, L.F.; Salio, M.; Griessinger, E.; Anjos-Afonso, F.; Craciun, L.; Chen, J.L.; Keller, A.M.; Joffre, O.; Zelenay, S.; Nye, E.; et al. Characterization of human dngr-1+ bdca3+ leukocytes as putative equivalents of mouse cd8alpha+ dendritic cells. J. Exp. Med. 2010, 207, 1261-1271.
78. Fonteneau, J.F.; Gilliet, M.; Larsson, M.; Dasilva, I.; Munz, C.; Liu, Y.J.; Bhardwaj, N. Activation of influenza virus-specific cd4+ and cd8+ t cells: A new role for plasmacytoid dendritic cells in adaptive immunity. Blood 2003, 101, 3520-3526.
79. Di Pucchio, T.; Chatterjee, B.; Smed-Sorensen, A.; Clayton, S.; Palazzo, A.; Montes, M.; Xue, Y.; Mellman, I.; Banchereau, J.; Connolly, J.E. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class i. Nat. Immunol. 2008, 9, 551-557.
80. Hoeffel, G.; Ripoche, A.C.; Matheoud, D.; Nascimbeni, M.; Escriou, N.; Lebon, P.; Heshmati, F.; Guillet, J.G.; Gannage, M.; Caillat-Zucman, S.; et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity 2007, 27, 481-492.
81. Diamond, M.S.; Kinder, M.; Matsushita, H.; Mashayekhi, M.; Dunn, G.P.; Archambault, J.M.; Lee, H.; Arthur, C.D.; White, J.M.; Kalinke, U.; et al. Type i interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 2011, 208, 1989-2003.
82. Fuertes, M.B.; Kacha, A.K.; Kline, J.; Woo, S.R.; Kranz, D.M.; Murphy, K.M.; Gajewski, T.F. Host type i ifn signals are required for antitumor cd8+ t cell responses through cd8{alpha}+ dendritic cells. J. Exp. Med. 2011, 208, 2005-2016.
83. Drobits, B.; Holcmann, M.; Amberg, N.; Swiecki, M.; Grundtner, R.; Hammer, M.; Colonna, M.; Sibilia, M., Imiquimod clears tumors in mice independent of adaptive immunity by converting pdcs into tumor-killing effector cells. J. Clin. Invest. 2012, 122, 575-585.
84. Liu, C.; Lou, Y.; Lizee, G.; Qin, H.; Liu, S.; Rabinovich, B.; Kim, G.J.; Wang, Y.H.; Ye, Y.; Sikora, A.G.; et al. Plasmacytoid dendritic cells induce nk cell-dependent, tumor antigen-specific t cell cross-priming and tumor regression in mice. J. Clin. Invest. 2008, 118, 1165-1175.
85. Mouries, J.; Moron, G.; Schlecht, G.; Escriou, N.; Dadaglio, G.; Leclerc, C. Plasmacytoid dendritic cells efficiently cross-prime naive t cells in vivo after tlr activation. Blood 2008, 112, 3713-3722.
86. Tel, J.; Aarntzen, E.H.; Baba, T.; Schreibelt, G.; Schulte, B.M.; Benitez-Ribas, D.; Boerman, O.C.; Croockewit, S.; Oyen, W.J.; van Rossum, M.; et al. Natural human plasmacytoid dendritic cells induce antigen-specific t-cell responses in melanoma patients. Cancer Res. 2013, 73, 1063-1075
87. Grote, D.; Cattaneo, R.; Fielding, A.K. Neutrophils contribute to the measles virus-induced antitumor effect: Enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res. 2003, 63, 6463-6468.
88. Liu, C.; Russell, S.J.; Peng, K.W. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol. Ther. 2010, 18, 1155-1164.
89. Mader, E.K.; Maeyama, Y.; Lin, Y.; Butler, G.W.; Russell, H.M.; Galanis, E.; Russell, S.J.; Dietz, A.B.; Peng, K.W. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin. Cancer Res. 2009, 15, 7246-7255.
90. Heo, J.; Reid, T.; Ruo, L.; Breitbach, C.J.; Rose, S.; Bloomston, M.; Cho, M.; Lim, H.Y.; Chung, H.C.; Kim, C.W.; et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia jx-594 in liver cancer. Nat. Med. 2013, 19, 329-336.
91. Taqi, A.M.; Abdurrahman, M.B.; Yakubu, A.M.; Fleming, A.F. Regression of Hodgkin's disease after measles. Lancet 1981, 1, 1112.
92. Zygiert, Z., Hodgkin's disease: Remissions after measles. Lancet 1971, 1, 593.
93. Ziegler, J.L. Spontaneous remission in burkitt's lymphoma. Natl. Cancer Inst. Monogr. 1976, 44, 61-65.
94. Heinzerling, L.; Kunzi, V.; Oberholzer, P.A.; Kundig, T.; Naim, H.; Dummer, R. Oncolytic measles virus in cutaneous t-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 2005, 106, 2287-2294.
95. ClinicalTrials. gov. Available online: http://www.clinicaltrials.gov/ (accessed on 12 December 2012).